The regulatory arc generates the highest question volume of any topic in the series. Andrew answers listener questions on MoCRA timelines, EU registration, the sunscreen monograph situation, OTC transition strategies, and adverse event reporting obligations.

IG: @manufacturingmadesimplepod

EU Cosmetics Regulation No. 1223/2009, the European Medicines Agency framework, ICH harmonization guidelines, and the challenge of building a global regulatory strategy across multiple overlapping frameworks. Andrew explains how to think about global compliance architecture before — not after — you decide which markets to enter.

IG:@Manufacturingmadesimplepod

NDAs, ANDAs, and the 505(b)(2) pathway — Andrew explains the FDA's pharmaceutical approval framework, why the clinical trial system works the way it does, how the OTC Drug Review monograph system was modernized under the CARES Act, and why the CMC section of any regulatory filing is where manufacturing quality meets regulatory strategy.

IG: @manufacturingmadesimplepod

The Modernization of Cosmetics Regulation Act (MoCRA) is the most significant update to US cosmetic regulation in nearly a century. Andrew explains its four pillars of facility registration, product listing, mandatory adverse event reporting, and forthcoming GMP regulations as well as what each one means operationally for manufacturers.

IG: @manufacturingmadesimplepod

Five more listener questions spanning formulation decision-making, the difference between contract and toll manufacturing, pharmaceutical IP protection, what clean beauty actually means from a regulatory standpoint, and how a personal care brand can move into producing their own OTC drug products.

IG: @manufacturingmadesimplepod

Every formula must satisfy three constraints simultaneously: efficacy, safety, and cost. Andrew explains how to navigate the trade-offs between all three in real product development decisions — including what "true cost" in formulation actually means beyond ingredient spend, and why safety is a hard constraint, not a variable.

IG: @manufacturingmadesimplepod

Every formula must satisfy three constraints simultaneously: efficacy, safety, and cost. Andrew explains how to navigate the trade-offs between all three in real product development decisions — including what "true cost" in formulation actually means beyond ingredient spend, and why safety is a hard constraint, not a variable.

IG: @manufacturingmadesimplepod

The pharmaceutical companion to Episode 3. Andrew covers active pharmaceutical ingredients, critical quality attributes, excipient selection across solid, liquid, and parenteral dosage forms, and the concept of bioavailability — the metric that connects formulation science to clinical reality.

IG: @manufacturingmadesimplepod

Andrew answers the first batch of listener questions and shares some insights to first had experiences he has seen.

IG: @manufacturingmadesimplepod

What's actually IN your shampoo, lotion, cleanser, and serum? Andrew breaks down core ingredients of emollients, humectants, surfactants, active ingredients, and explains what each one does.